What to plan for a Peoria joint visit

What to confirm before arranging a ride

QC Kinetix has a Peoria clinic at 13128 N. 94th Dr., Suite 205, Peoria, AZ 85381. Phoenix-area locations all use one number: (602) 837-PAIN / (602) 837-7246.

A consultation and exam may allow driving afterward. Ask the clinic whether a blood, marrow, fat or joint procedure requires a driver.

What to bring for the joint exam

Bring your medicine list, old X-ray report and notes from earlier care. Wear clothes that leave the aching joint easy to reach.

The clinician will review your health and examine the sore joint. Ask whether blood draw, pelvic marrow removal or fat removal would happen later.

What to set up for the first days home

Put often-used items where you can reach them without bending or stairs. Plan simple meals and some help if you can't drive.

Ask when walking, golf and pickleball may begin again. Get clear limits for each activity instead of general advice to rest.

When to call the clinic after hours

Keep the office number beside the written care note. The note should separate expected soreness from fever, heat or growing swelling.

Follow the clinic's urgent-care directions if the office can't be reached. Severe symptoms or swelling that grows fast may need emergency care.

Sources

1. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

2. A systematic review of 32 studies comparing leukocyte-poor and leukocyte-rich PRP in knee OA found both formulations improved pain and function above the MCID with no significant difference between them at 3, 6 or 12 months - but leukocyte-RICH PRP carried significantly higher odds of post-injection pain (OR 1.64; 95% CI 1.29-2.10) and swelling (OR 1.56; 95% CI 1.22-1.99).

   Kim JH, et al. — Adverse Reactions and Clinical Outcomes for Leukocyte-Poor Versus Leukocyte-Rich Platelet-Rich Plasma in Knee Osteoarthritis: A Systematic Review and Meta-analysis.. Orthopaedic Journal of Sports Medicine, 2021. DOI: 10.1177/23259671211011948.

3. The AAOS patient-education FAQ on orthobiologics states that because orthobiologics are relatively new the evidence supporting their use is LIMITED, that rigorous testing of effectiveness in most orthopedic conditions is lacking, and that preliminary results are encouraging but hard to evaluate. It names tendinopathies such as tennis elbow, pain from early knee osteoarthritis, adjunct healing after rotator cuff repair, and avascular necrosis as the settings where biologic therapies have shown promise, and notes that stem cell treatments not derived from the patient's own body and further manipulated in a laboratory can only be offered inside an FDA-approved clinical trial.

   American Academy of Orthopaedic Surgeons — Orthobiologics (Regenerative Medicine) FAQ. OrthoInfo (AAOS), 2024.

4. A 2026 systematic review of leukocyte-rich versus leukocyte-poor PRP for osteoarthritis concluded the current evidence is insufficient to determine whether adding leukocytes provides any clinical benefit, that results generally show no significant difference between the two, and that there is no conclusive evidence local reactions are caused by leukocytes specifically.

   Martin-Vega M, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review.. Regenerative Therapy, 2026. DOI: 10.1016/j.reth.2026.101078.

5. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.